Cipla Resets Biosimilars Interest, Readies Respiratory-Focused JV
Cipla moves beyond in-licensing approach and teams up with CDMO Kemwell to develop and progress respiratory biosimilars. Commercialization of products anticipated post 2025.
Cipla moves beyond in-licensing approach and teams up with CDMO Kemwell to develop and progress respiratory biosimilars. Commercialization of products anticipated post 2025.